[{"address1": "2001 Market Street", "address2": "Suite 3915 Unit #15", "city": "Philadelphia", "state": "PA", "zip": "19103", "country": "United States", "phone": "(267) 225-7416", "website": "https://www.contexttherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.", "fullTimeEmployees": 5, "companyOfficers": [{"maxAge": 1, "name": "Mr. Martin A. Lehr", "age": 39, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 674083, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Minai-Azary", "age": 45, "title": "CFO & Treasurer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 504143, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex C. Levit Esq.", "age": 44, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 483831, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Beck M.B.A.", "title": "Senior Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.95, "open": 1.88, "dayLow": 1.88, "dayHigh": 2.0, "regularMarketPreviousClose": 1.95, "regularMarketOpen": 1.88, "regularMarketDayLow": 1.88, "regularMarketDayHigh": 2.0, "forwardPE": -6.25, "volume": 180288, "regularMarketVolume": 180288, "averageVolume": 573370, "averageVolume10days": 282600, "averageDailyVolume10Day": 282600, "marketCap": 149996608, "fiftyTwoWeekLow": 0.77, "fiftyTwoWeekHigh": 2.1, "fiftyDayAverage": 1.49722, "twoHundredDayAverage": 1.18688, "currency": "USD", "enterpriseValue": 139907424, "floatShares": 65241782, "sharesOutstanding": 74998304, "sharesShort": 6533, "sharesShortPriorMonth": 11223, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.02781, "heldPercentInstitutions": 0.27163, "shortRatio": 0.11, "shortPercentOfFloat": 0.0004, "impliedSharesOutstanding": 78075200, "bookValue": 0.529, "priceToBook": 3.7807186, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -21323690, "trailingEps": -1.33, "forwardEps": -0.32, "enterpriseToEbitda": -6.297, "52WeekChange": 1.0408163, "SandP52WeekChange": 0.26137078, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CNTX", "underlyingSymbol": "CNTX", "shortName": "Context Therapeutics Inc.", "longName": "Context Therapeutics Inc.", "firstTradeDateEpochUtc": 1634736600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9370db4d-3fc8-33de-8dd0-aba14eeca611", "messageBoardId": "finmb_408000800", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.0, "targetHighPrice": 10.0, "targetLowPrice": 2.1, "targetMeanPrice": 5.4, "targetMedianPrice": 4.75, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 10089207, "totalCashPerShare": 0.135, "ebitda": -22218150, "quickRatio": 3.868, "currentRatio": 4.232, "returnOnAssets": -0.64594, "returnOnEquity": -1.1471701, "freeCashflow": -12231230, "operatingCashflow": -19679784, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-27"}]